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Genotype and Phenotype in Ehlers-Danlos Syndrome Type IV 
Smith el "I (p. 241) show that mutati ons in the region of the 
COL3Al gene coding for the triple helix affect the size and 
d is tribution of dermal co ll agen fibril s in patients with Eh lers-Danlos 
Syndrome (EDS) Type IV. T hese patients have extreme ly fra gil e 
tissues and arc at hi gh ri sk for arteria l, bowel. and uterin e rupture, 
a nd their skin is thin and bruises easily. T he authors note that both 
(i) the amount and size of colJagen fibril s in the dermis and also (ii) 
the ex tent of dilation o f the rough endoplasmic reticulum (RE R) in 
fibro blasts were quite variable in different patients and wondered 
w h ether the variability could be related to the type or position of 
[he mutation. To stud y this question, they compared the diameters 
of colJagen ~ibrils by electron mi croscopy in patients with known 
mutations. I30th substitutions for glycine and exon skipping muta-
tions in the carboxyl-terminal end of the trip le heli x were associ-
ated with reduced fibril diam eter and dilated RER. (Di lated R E R 
is tho ught to be rel ated to defective secretion of newly synth esized 
abnorma l coll agen.) In contrast, chan ges ncar the atni no-tennina l 
end of the trip le helical domain w ere associa ted with variable 
diam eters of th e fibrils and less evidence of intracellul ar retention of 
the abnorma l protein . T he J'esults suggest that different typ es of 
structural changes in colla gen fibrils ma y refl ect the specific l11uta-
tions; i.e. , the alterations m ay be characteristic of the mutation. 
Beca use the EDS phe notype was simi lar in the patients studied, 
however, the redu ced amount o f normal type III collagen. not the 
variati on in fibri l diameter, may be the m os t important f.1 c tor in 
determining th e clini ca l findings. 
A Possible Role for TIMP-l in Scleroderma 
Kikuchi el al (p. 281) report th at T IMP-1may be an alltocrill c growth 
fac tor, that is , a f.'1ctor both secreted by and acting on adjacent 
fibro blasts, in scleroderm a. Severa l reports have described e levated 
mitogenic acti vity for dermal fibroblasts in the sera of scleroderma 
patients. R ecentl y, T IMP-l , which antagon izes collagenase activ-
ity, has been shown to be mitogeni c for dermal fibroblasts. T he 
a uthors thought T IMP-1 , which was elevated in sera of sclero-
derma patients. mig ht be in vo lved in the activation of fibroblasts 
derived fi'om scleroderma skin and therefore in vestigated both the 
mitogenic response to T IMP-l and also T IMP-l exp ression in 
scleroderma fibroblasts. T he mitogenic response to TIMP-1 in 
scleroderma fibroblasts was in creased over that in contro ls , and 
antibod y to TIMP-'I blocked the basa l mitogenic activity ofsclero-
derma fibroblasts, supporting a role for TIMP-l ill the regulation of 
fibrob last proliferation. Scleroderma fibro blasts produced increased 
amounts of T IM P-1 protein and m R.N A . T ransfo rming growth 
facto r-{3 (TGF-(3) , thou ght to be a critical cytokine in fibrosis , is 
also a potent indu cer of T IM P-1. and the auth ors fo und that TGF-f3 
upregulated T IMP- l production in normal fibro blasts. but not in 
sclero derma tibrobl as ts. T hi s might re fl ect the earl y excessive 
exposure to TGF-{3 ill /Ii llo in scleroderma fibroblasts. T hese ob-
servations suggest that T IMP-l might be invo lved not o nl y in the 
co ll agen accumu lation , but also in the fibro blast proliferation 
accompanying fibro sis in scleroderma. Antagoniz ing TIMP-1 might 
reclu ce dermal fibrosi s. 
Modulating Fibrosis 111 Wounded Skin 
Meisler el nl (p. 285) ha ve found that dexamethasone abrogates the 
fibrogenic effect of tran sfo rmin g growth f.1cto r-{3 (TGF-{3). I t had 
been known for some time that dexamethaso ne can antagonize the 
effects of TGF-f3. Since TGF-f3 is known to in crease co llagen 
synthesis while dexamethason e decreases it, the investigators asked 
w h e ther dexamethason e could prevent the fibrosis stimulated by 
TGF-{3. When sma ll sponges were pla ced ill the skin of rats and 
exam.inecl for m easures of collagen content, dexamethasone wa s 
found to block the increase in hyd roxypro line produced by TGF- {3. 
Similar results were found when granulation tiss ue fibroblasts were 
treated with TGF-FJ and dexametha sone . "Bimodal" therapy in-
volving the usc of both TGF-/3 and dexamethasone ma y promote 
wou nd healing w ithout the excessive sca rring tha t re fl ec ts in creased 
c.o llagen deposition and migh t be used to enhan ce no rmal repaiJ·. 
for example in second-degree burns. 
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Gene Therapy for W oLlnd Healing 
Sun el 411 (p. 313) dem o nstrate that a trnnsfection with the gene for 
FG F-1 can improve wo und healing in skin . T here is experimental 
evidence th>l r wound healin g is enhanced by growth fac tors includ-
ing FGF- ] (;oc idic fibl'oblll st gt"Owth fa ctor). [ t ha s been unclea r, 
however , whether in creasing the expressio n of the FG F-l gene in 
rh e healing tis5 ul.! , and increasin g express ion o f tha t genl.! aJone, 
might be benefi cial. The iJwescigato rs used a plasmid contajJ]ing the 
gene fo r human FGF-1 spliced to the D N A fo r a signal peptide (to 
ensure pro mpt secre tio n) and in troduced the plasmid into skin 
wounds in mi ce eithe r by direct injectio n o r by topi ca l applicatio n . 
T he transcription and expression o f the gene were increased and 
then eventuall y declined , suggesting tha t th e fo re ign gc." ne Was 
gradually shed o r that expression of the fore ign gene was increas~ 
ing ly repressed. T he transfection in creased the rate of wottt1d 
closure and breaking stren gth of the w ound . T hese rewlb lead th e 
investigators to beli eve th at direct appliciltion of genes m;l)' be 
adVal1t;l geoll s over other methods. 
Which R eceptor Binds IgE in the Skin in Atopic Dermatitis? 
rClubal el !I/ (p. 336) presen t evidence tha t FCERl is the critical 
19B-bind ing structure in acopic dermati tis skin . While the presence 
of JgE ce lls in atopic dermatiti s .Iesions hlls lon g been es tablished , 
the nature o f the IgE-binding moie ties has remained enigmatic. 
T hree dilferent stru ctures, the low-aftini ty IgE receptor, the high-
aflinity 19B receptor, and gal ectin-3 , an 19B-binding cell-surface 
lectin, have been shown to hUld IgE ill vitro. In o rder to de te rmine 
which of tbese structures actually binds the IgE m olecules in atopic 
dermatitis ill VilIV, KJubal ('/ 01 removed IgE £i'0111 cryostat secti ons of 
skin fi-O Ill ,ltopic dermatitis patients and then examined th e rebind-
in g of rgE to these skin sections. By usin g difrerent an tibodies 
capable of blockin g binding to each of the three IgE-blnding 
stru ctures, they were abl e co stud y the contributi on o f each to the 
overall binding of IgE. IgE binding could be pre vented by a 
l11o noclon~ 1 antibody directed against th e a -chain ofFcElU, bu t n Ot 
by reagen ts blocking f CERJl /C D23 or galectin-3. Iml11ul1olabelill g 
studies revealed th;lt the vast majOlity of the IgE-binding celis 
belong to thl! Langerhans cc llldclldritic cell linea ge. Since there a re 
large numbers of FCEl~1 + dendritic antigen-presentiJlg cell s ill 
lesiollS o f atopic derm atitis, these resul ts indicate that FCEl'U is th e 
predorninant and cer tainly the bio logica lly most relevant rgE-
binding st1'l1 cture in atopic derl11atitis. Beca use FCEIU is now 
recognized as a signal-tral1 sdu ing unit on antigen-presentin g celis, 
mas t cell s, and perhaps eosinophils, i. e ., cells criticall y invol ved i~ 
atopi c ti ssue inR 'lmm,ltion. FCERI is an attra ctive target for therapy 
o f ato pi c dermatitis. 
Homing Lymphocytes That Distingujsh Papillary From R eticular Dermis 
KUlJ stfe ld e/ III (p . 343) show that Iymph ocytcs expressin g th e 
cut;lIl CO US lymph ocyte anti gen (C LA) can discriminate between the 
superfi cia l and deep vascular pl exuses in th e skin . Lymphocyte 
t raffic fro m th e blood stream in to th e tissue is co ntro ll ed by 
adh esion molecules on endo the lium that bind to othel' adh esion 
molecules OlJ inflaml11<lto ry cells. When the pairing molecules are 
express 'd and bind to each odl el', they mediate a cascade of events 
leadin g to adh esion co lymphocytes to th e vascubr wa U and 
mi gra tio n through ic, but when che appropria te pairs of adhesion 
m o lecules are not expressed, these adhesive events te rmjnate and , 
as a consequence, the inflaml11;lcory response is te rminated . T iss ll e 
specifi c lymph ocyte ho min g can be produced by the expression of 
tiss lle specifi c ;tdhesion J110lecltlcs by eithe r endothelium or lym-
phocytes, and mol ec ul es have indeed been identified that control 
lymphocyte traffi c to lymph nodes or g ut. R ecentl y, a skin-specifi c 
m o lecule expressed by lymphocytes, the C LA, has been described . 
It is recognized by the monoclonal antibody HECA452 and is 
th ought to contro l traffic o f lymphocytes in skin. CLA is fouu d 
primaril y on skin-infiltrating T cells and is thought to mediate 
skin-specific binding o f lymph ocytes. In order to study the mle of 
CL A ill skin. Kunstfeld ct (II grafted the supe rficial and deep vascula r 
plex uses from th e same dono r separatel y onto the back o f a SCID 
mo use , inj ected allogeneic human T ce lls in to the peri toneal cavity, 
,ll1d then de termined wh,1t types of cells became localized in th e 
sllperti cial and deep picXlIS sampl es. Fourteen days afte r th e 
injectio n, both superfic ial and deep vascular pl exus skin samples 
were densely infiltrn ~ed wirh hum,lIl T celJ ~. but C LA-posit ive T 
cells Wl:re fo und only ill the superficial vascular plexus. These da ta 
indi cate tha t CtA enahles human lymphocytes to discriminate n Ot 
onl y between skiJl and other o rg;lI1s, but also between differen r 
vascular beds- the superfi cial and deep vascular plex us-with.in the 
skin . 
